PEAQX: Difference between revisions
Content deleted Content added
Updating {{drugbox}} (no changed fields - added verified revid - updated 'ChemSpiderID_Ref', 'DrugBank_Ref', 'UNII_Ref', 'ChEMBL_Ref', 'ChEBI_Ref', 'KEGG_Ref', 'StdInChI_Ref', 'StdInChIKey_Ref', 'ChEBI_Ref') per [[WP:CHEMVALID|Chem/Drugbox validation |
No edit summary |
||
| Line 36: | Line 36: | ||
| molecular_weight = 454.211 g/mol |
| molecular_weight = 454.211 g/mol |
||
| smiles = O=c2nc1c(nc2=O)cccc1C(P(O)(O)=O)NC(C)c3ccc(Br)cc3 |
| smiles = O=c2nc1c(nc2=O)cccc1C(P(O)(O)=O)NC(C)c3ccc(Br)cc3 |
||
| synonyms = PEAQX |
| synonyms = PEAQX, NVP-AAM077 |
||
}} |
}} |
||
Revision as of 13:07, 4 September 2012
 | |
| Clinical data | |
|---|---|
| Other names | PEAQX, NVP-AAM077 |
| Identifiers | |
| |
| Chemical and physical data | |
| Formula | C17H17BrN3O5P |
| Molar mass | 454.211 g/mol g·mol−1 |
| 3D model (JSmol) | |
| |
| (verify) | |
PEAQX is a competitive antagonist at the NMDA receptor. Although originally described as 100-fold selective for GluN1/GluN2A receptors vs. GluN1/GluN2B receptors, more detailed studies[1] of the Ki of PEAQX revealed it only shows a 5 fold difference in affinity for GluN1/GluN2A vs. GluN1/GluN2B receptors. It is also a potent anticonvulsant in animal tests.[2]
References
- ^ Frizelle PA, Chen PE, Wyllie DJ Equilibrium constants for (R)-[(S)-1-(4-bromo-phenyl)-ethylamino]-(2,3-dioxo-1,2,3,4-tetrahydroquinoxalin-5-yl)-methyl]-phosphonic acid (NVP-AAM077) acting at recombinant NR1/NR2A and NR1/NR2B N-methyl-D-aspartate receptors: Implications for studies of synaptic transmission. Molecular Pharmacology 2006 Sep;70(3):1022-32. PMID 16778008
- ^ Auberson YP, Allgeier H, Bischoff S, Lingenhoehl K, Moretti R, Schmutz M. 5-Phosphonomethylquinoxalinediones as competitive NMDA receptor antagonists with a preference for the human 1A/2A, rather than 1A/2B receptor composition. Bioorganic and Medicinal Chemistry Letters. 2002 Apr 8;12(7):1099-102. PMID 11909726